Rastilav Bahleda

Villejuif, 94805, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

HMGA2::NCOR2 fusion-driven giant cell tumors: Diagnosis and treatment.

HMGA2::NCOR2 fusion-driven giant cell tumors: Diagnosis and treatment.

Journal: Critical reviews in oncology/hematology

Published: February 13, 2026

Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis.

Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis.

Journal: Cancer treatment reviews

Published: December 23, 2024

Association of Lung Immune Prognostic Index (LIPI) with Disease Control Rate and Progression-Free Survival in Patients with Soft-Tissue Sarcoma Treated with Immunotherapy in Early-Phase Trials.

Association of Lung Immune Prognostic Index (LIPI) with Disease Control Rate and Progression-Free Survival in Patients with Soft-Tissue Sarcoma Treated with Immunotherapy in Early-Phase Trials.

Journal: Cancers

Published: October 22, 2024

Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results.

Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results.

Journal: Signal transduction and targeted therapy

Published: September 24, 2024

Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab.

Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab.

Journal: Signal transduction and targeted therapy

Published: August 01, 2024

A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors.

A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors.

Journal: Cancer research communications

Published: March 05, 2024

Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review.

Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review.

Journal: Current treatment options in oncology

Published: September 24, 2023

An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer.

An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer.

Journal: Molecular cancer

Published: September 19, 2023

Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology.

Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology.

Journal: JCO precision oncology

Published: October 31, 2022

Epigenetic gene alterations in metastatic solid tumours: results from the prospective precision medicine MOSCATO and MATCH-R trials.

Epigenetic gene alterations in metastatic solid tumours: results from the prospective precision medicine MOSCATO and MATCH-R trials.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 28, 2022

PALLIA 10 score in phase I cancer studies.

PALLIA 10 score in phase I cancer studies.

Journal: BMJ supportive & palliative care

Published: February 28, 2022

Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic.

Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic.

Journal: Cancer cell

Published: July 01, 2021

Showing 1-12 of 30

Last Updated: 09/26/2026